GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease


 7 November 2017 - GlaxoSmithKline today announced the submission of a supplemental biologics license application to the United States FDA, seeking approval of mepolizumab, an interleukin-5 antagonist, as an add-on to maintenance treatment for patients who have chronic obstructive pulmonary disease with an eosinophilic phenotype.

The submission includes phase III data from the previously reported METREX and METREO studies.

Read GSK press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Submission